{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"PD, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"PD, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Death in absence of PD, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Death in absence of PD, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Events, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Events, No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from the date of registration of the patient to either the date of disease progression or the date of death (for whatever reason), whichever came first. Patients alive and without disease progression were censored at the date of their last tumor evaluation. PFS events included progressive disease (PD), death in absence of PD and events (Any event which was part of the natural course of the disease under study, was captured as an efficacy measure. Therefore it did not need to be reported as an SAE).","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis was performed on the total treated cohort (TTC), which included all subjects who received at least one dose of the Antigen-Specific Cancer Immunotherapeutic (ASCI) treatment.","reportingStatus":"POSTED","timeFrame":"From first treatment administration (i.e. at Week 0) until the last tumor evaluation (i.e. at Month 49)","title":"Number of Patients With Progression-free Survival Events","type":"SECONDARY","unitOfMeasure":"Participants"}